Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions

shigeo koido Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan; Institute of Clinical Medicine and Research; The Jikei University School of Medicine; Tokyo, Japan; Department of Oncology; Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, JapanCorrespondence[email protected]

Sadamu Homma Department of Oncology; Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, Japan

Masato Okamoto Division of Cellular Signaling; Institute for Advanced Medical Research; Keio University School of Medicine; Tokyo, Japan

Yoshihisa Namiki Institute of Clinical Medicine and Research; The Jikei University School of Medicine; Tokyo, Japan

Kazuki Takakura Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

Kan Uchiyama Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

Mikio Kajihara Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

Seiji Arihiro Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

Hiroo Imazu Department of Endoscopy; The Jikei University School of Medicine; Tokyo, Japan

Hiroshi Arakawa Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan; Department of Endoscopy; The Jikei University School of Medicine; Tokyo, Japan

Shin Kan Department of Oncology; Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, Japan

Hideo Komita Department of Oncology; Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, Japan

Yuko Kamata Department of Oncology; Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, Japan

Masaki Ito Department of Oncology; Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, Japan

Toshifumi Ohkusa Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

Jianlin Gong Department of Medicine; Boston University School of Medicine; Boston, MA USA

Hisao Tajiri Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

show all

Abstract

The rationale for fusing dendritic cells (DCs) with whole tumor cells to generate anticancer vaccines resides in the fact that the former operate as potent antigen-presenting cells, whereas the latter express a constellation of tumor-associated antigens (TAAs). Although the administration of DC/malignant cell fusions to cancer patients is safe and this immunotherapeutic intervention triggers efficient tumor-specific T-cell responses in vitro, a limited number of objective clinical responses to DC/cancer cell fusions has been reported thus far. This review discusses novel approaches to improve the immunogenicity of DC/malignant cell fusions as anticancer vaccines.

Keywords::

Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions

Related Research Data

Information for

Open access

Opportunities

Help and information

Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions

Abstract

Related Research Data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature